Skip to content
TheChatArchiveThe Chat Archive
gpt-4-0613· OpenAIHugging Face Arena Human Preference 55K

Which anti-LAG3 candidate has the most promising clinical data?

From a Chatbot Arena battleThe same person sent this prompt to two anonymous models at once. Compare it with Geminigemini-pro-dev-api’s answer.
  1. User

    Which anti-LAG3 candidate has the most promising clinical data?

  2. Assistant

    As an AI, I don't have real-time access to data, so I can't provide the current most promising anti-LAG3 candidate. However, as of my last update, Bristol-Myers Squibb's relatlimab (anti-LAG3) was showing promising results in clinical trials. Combined with nivolumab, it demonstrated increased progression-free survival rates in patients with metastatic or unresectable melanoma. Please consult the latest research or a healthcare professional for the most recent and accurate information.

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.